Lipid Nanoparticle-Based Inhibitors for SARS-CoV-2 Host Cell Infection

Yathindranath et al., International Journal of Nanomedicine, doi:10.2147/IJN.S448005, Mar 2024
In vitro study showing that lactoferrin, camostat mesylate, and carrageenan inhibit SARS-CoV-2 pseudovirus infection in airway epithelial Calu-3 cells. All show dose-dependent inhibition. The study focuses on novel LNP formulations and the combination of carrageenan with the authors' LNP-PEP formulation containing ACE2 peptide showed significantly higher inhibition compared to carrageenan alone.
18 preclinical studies support the efficacy of lactoferrin for COVID-19:
Study covers iota-carrageenan, lactoferrin, and TMPRSS2 inhibitors.
Yathindranath et al., 28 Mar 2024, peer-reviewed, 5 authors. Contact: donald.miller@umanitoba.ca.
In vitro studies are an important part of preclinical research, however results may be very different in vivo.
Lipid Nanoparticle-Based Inhibitors for SARS-CoV-2 Host Cell Infection
Vinith Yathindranath, Nura Safa, Mateusz Marek Tomczyk, Vernon Dolinsky, Donald W Miller
International Journal of Nanomedicine, doi:10.2147/ijn.s448005
Purpose: The global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the lingering threat to public health has fueled the search for effective therapeutics to treat SARS-CoV-2. This study aimed to develop lipid nanoparticle (LNP) inhibitors of SARS-CoV-2 entry to reduce viral infection in the nose and upper airway. Methods: Two types of LNP formulations were prepared following a microfluidic mixing method. The LNP-Trap consisted of DOPC, DSPC, cholesterol, and DSPE-PEG-COOH modified with various spike protein binding ligands, including ACE2 peptide, recombinant human ACE2 (rhACE2) or monoclonal antibody to spike protein (mAb). The LNP-Trim consisted of ionizing cationic DLin-MC3-DMA, DSPC, cholesterol, and DMG-PEG lipids encapsulating siACE2 or siTMPRSS2. Both formulations were assayed for biocompatibility and cell uptake in airway epithelial cells (Calu-3). Functional assessment of activity was performed using SARS-CoV-2 spike protein binding assays (LNP-Trap), host receptor knockdown (LNP-Trim), and SARS-CoV-2 pseudovirus neutralization assay (LNP-Trap and LNP-Trim). Localization and tissue distribution of fluorescently labeled LNP formulations were assessed in mice following intranasal administration. Results: Both LNP formulations were biocompatible based on cell impedance and MTT cytotoxicity studies in Calu-3 cells at concentrations as high as 1 mg/mL. LNP-Trap formulations were able to bind spike protein and inhibit pseudovirus infection by 90% in Calu-3 cells. LNP-Trim formulations reduced ACE2 and TMPRSS2 at the mRNA (70% reduction) and protein level (50% reduction). The suppression of host targets in Calu-3 cells treated with LNP-Trim resulted in over 90% inhibition of pseudovirus infection. In vivo studies demonstrated substantial retention of LNP-Trap and LNP-Trim in the nasal cavity following nasal administration with minimal systemic exposure. Conclusion: Both LNP-Trap and LNP-Trim formulations were able to safely and effectively inhibit SARS-CoV-2 pseudoviral infection in airway epithelial cells. These studies provide proof-of-principle for a localized treatment approach for SARS-CoV-2 in the upper airway.
Disclosure
References
Ahn, Kim, Hong, Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19, J Clin Investig, doi:10.1172/JCI148517
Arias, Oliveros, Lechtig, Bustos, Biologics in COVID-19 so far: systematic review, Pharmaceuticals, doi:10.3390/ph15070783
Baram-Pinto, Shukla, Gedanken, Sarid, Inhibition of HSV-1 attachment, entry, and cell-to-cell spread by functionalized multivalent gold nanoparticles, Small, doi:10.1002/smll.200902384
Bayón-Cordero, Alkorta, Arana, Application of solid lipid nanoparticles to improve the efficiency of anticancer drugs, Nanomaterials, doi:10.3390/nano9030474
Belliveau, Huft, Lin, Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA, Mol Ther Nucleic Acids, doi:10.1038/mtna.2012.28
Bowman, Ballard, Ackerson, Feldheim, Margolis et al., Inhibition of HIV fusion with multivalent gold nanoparticles, J Am Chem Soc, doi:10.1021/ja710321g
Cahn, Amosu, Maisel, Duncan, Biomaterials for intranasal and inhaled vaccine delivery, Nat Rev Bioeng, doi:10.1038/s44222-022-00012-6
Chan, Tan, Narayanan, Procko, An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants, Sci Adv, doi:10.1126/sciadv.abf1738
Chen, Cheng, Roffler, Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies, ACS Nano, doi:10.1021/acsnano.1c05922
Chen, Fang, Chen, Targeting and enrichment of viral pathogen by cell membrane cloaked magnetic nanoparticles for enhanced detection, ACS Appl Mater Interfaces, doi:10.1021/acsami.7b09931
El-Shennawy, Hoffmann, Dashzeveg, Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2, Nat Commun, doi:10.1038/s41467-021-27893-2
Giovane, Rezai, Henderson, Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: a review, Rev Med Virol, doi:10.1002/rmv.2136
Gizurarson, The relevance of nasal physiology to the design of drug absorption studies, Adv Drug Deliv Rev, doi:10.1016/0169-409X(93)90015-V
Gong, -J Y, PTD4-apoptin protein and dacarbazine show a synergistic antitumor effect on B16-F1 melanoma in vitro and in vivo, Eur J Pharmacol, doi:10.1016/j.ejphar.2010.12.004
Gottlieb, Nirula, Chen, Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial, JAMA, doi:10.1001/jama.2021.0202
Hak, Helgesen, Hektoen, The effect of nanoparticle polyethylene glycol surface density on ligand-directed tumor targeting studied in vivo by dual modality imaging, ACS Nano, doi:10.1021/nn301630n
Han, Penn-Nicholson, Cho, Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor, International Journal of Nanomedicine, doi:10.1016/j.virol.2006.01.029
Haschke, Schuster, Poglitsch, Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects, Clin Pharmacokinet, doi:10.1007/s40262-013-0072-7
Higuchi, Suzuki, Arimori, Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2, Nat Commun, doi:10.1038/s41467-021-24013-y
Hoffmann, Hofmann-Winkler, Smith, Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity, EBioMedicine, doi:10.1016/j.ebiom.2021.103255
Hoffmann, Kleine-Weber, Schroeder, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, doi:10.1016/j.cell.2020.02.052
Hou, Zaks, Langer, Dong, Lipid nanoparticles for mRNA delivery, Nat Rev Mater, doi:10.1038/s41578-021-00358-0
Huang, Leobandung, Foss, Peppas, Molecular aspects of muco-and bioadhesion: tethered structures and site-specific surfaces, J Control Release, doi:10.1016/S0168-3659(99)00233-3
Jia, Yue, Lazartigues, ACE2 mouse models: a toolbox for cardiovascular and pulmonary research, Nat Commun, doi:10.1038/s41467-020-18880-0
Kreuzberger, Hirsch, Chai, SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19, Cochrane Database Syst Rev, doi:10.1002/14651858.CD013825.pub2
Kuba, Yamaguchi, Penninger, Angiotensin-Converting Enzyme 2 (ACE2) in the pathogenesis of ARDS in COVID-19, Front Immunol, doi:10.3389/fimmu.2021.732690
Martinez-Avila, Hijazi, Marradi, Gold manno-glyconanoparticies: multivalent systems to block HIV-1 gp120 binding to the lectin DC-SIGN, Chem Eur J, doi:10.1002/chem.200900923
Mesias, Zhu, Tang, Effective ACE2 peptide-nanoparticle conjugation and its binding with the SARS-Cov-2 RBD quantified by dynamic light scattering, Chem Comm, doi:10.1039/D1CC02267A
Nathan, Shawa, De, Torre, A narrative review of the clinical practicalities of bamlanivimab and etesevimab antibody therapies for SARS-CoV-2, Infect Dis Ther, doi:10.1007/s40121-021-00515-6
Nikiforuk, Kuchinski, Twa, The contrasting role of nasopharyngeal angiotensin converting enzyme 2 (ACE2) transcription in SARS-CoV-2 infection: a cross-sectional study of people tested for COVID-19 in British Columbia, Canada, International Journal of Nanomedicine, doi:10.1016/j.ebiom.2021.103316
Niknam, Jafari, Golchin, Potential therapeutic options for COVID-19: an update on current evidence, Eur J Med Res, doi:10.1186/s40001-021-00626-3
Panahi, Gorabi, Talaei, An overview on the treatments and prevention against COVID-19, Virol J, doi:10.1186/s12985-023-01973-9
Papp, Sieben, Ludwig, Inhibition of influenza virus infection by multivalent sialic-acid-functionalized gold nanoparticles, Small, doi:10.1002/smll.201001349
Planas, Veyer, Baidaliuk, Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization, Nature, doi:10.1038/s41586-021-03777-9
Polack, Thomas, Kitchin, Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine, N Engl J Med, doi:10.1056/NEJMoa2034577
Politch, Cu-Uvin, Moench, Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (MB66): a Phase I randomized trial, PLoS Med, doi:10.1371/journal.pmed.1003495
Pustake, Tambolkar, Giri, Gandhi, SARS, MERS and CoVID-19: an overview and comparison of clinical, laboratory and radiological features, J Family Med Prim Care, doi:10.4103/jfmpc.jfmpc_839_21
Rao, Xia, Xu, Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines, Proc Natl Acad Sci, doi:10.1073/pnas.2014352117
Ren, Wang, Gao, Zhou, Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance, World J Clin Cases, doi:10.12998/wjcc.v10.i1.1
Schütz, Ruiz-Blanco, Münch, Kirchhoff, Sanchez-Garcia et al., Peptide and peptide-based inhibitors of SARS-CoV-2 entry, Adv Drug Deliv Rev, doi:10.1016/j.addr.2020.11.007
Scopes, Measurement of protein by spectrophotometry at 205 nm, Analy Biochem, doi:10.1016/0003-2697(74)90034-7
Semple, Klimuk, Harasym, Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures, Biochim Biophys Acta, doi:10.1016/S0005-2736(00)00343-6
Serra, Doménech, Peppas, Design of poly(ethylene glycol)-tethered copolymers as novel mucoadhesive drug delivery systems, CAS, SciSearch ® , Current Contents ® /Clinical Medicine, Journal Citation Reports/Science Edition, doi:10.1016/j.ejpb.2005.10.011
Sneller, Blazkova, Justement, Combination anti-HIV antibodies provide sustained virological suppression, Nature, doi:10.1038/s41586-022-04797-9
Sullivan, Gebo, Shoham, Early outpatient treatment for Covid-19 with convalescent plasma, N Engl J Med, doi:10.1056/NEJMoa2119657
Sungnak, Huang, Bécavin, SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes, Nat Med, doi:10.1038/s41591-020-0868-6
Tam, Chen, Cullis, Advances in lipid nanoparticles for siRNA delivery, Pharmaceutics, doi:10.3390/pharmaceutics5030498
Tam, Kulkarni, An, Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways, Eur J Pharm Sci, doi:10.1016/j.ejps.2022.106234
V'kovski, Kratzel, Steiner, Stalder, Thiel, Coronavirus biology and replication: implications for SARS-CoV-2, Nat Rev Microbiol, doi:10.1038/s41579-020-00468-6
Valenti, Antonini, Lactoferrin: an important host defence against microbial and viral attack. Cellular and molecular life sciences, Cell Mol Life Sci, doi:10.1007/s00018-005-5372-0
Van Der Meel, Chen, Zaifman, Modular lipid nanoparticle platform technology for siRNA and lipophilic prodrug delivery, Small, doi:10.1002/smll.202103025
Walsh, Seaman, Broadly neutralizing antibodies for HIV-1 prevention, Front Immunol, doi:10.3389/fimmu.2021.712122
Wei, Zhang, Ran, T-cell-mimicking nanoparticles can neutralize HIV infectivity, Adv Mater, doi:10.1002/adma.201802233
Wotring, Fursmidt, Ward, Sexton, Evaluating the in vitro efficacy of bovine lactoferrin products against SARS-CoV-2 variants of concern, J Dairy Sci, doi:10.3168/jds.2021-21247
Xu, Ensign, Boylan, Impact of Surface Polyethylene Glycol (PEG) density on biodegradable nanoparticle transport in mucus ex vivo and distribution in vivo, ACS Nano, doi:10.1021/acsnano.5b03876
Yang, Rao, Structural biology of SARS-CoV-2 and implications for therapeutic development, Nat Rev Microbiol, doi:10.1038/s41579-021-00630-8
Yathindranath, Safa, Sajesh, Spermidine/Spermine N1-Acetyltransferase 1 (SAT1)-A potential gene target for selective sensitization of glioblastoma cells using an ionizable lipid nanoparticle to deliver siRNA, Cancers, doi:10.3390/cancers14215179
Zhao, Wu, Heberle, Phase studies of model biomembranes: complex behavior of DSPC/DOPC/cholesterol, Biochim Biophys Acta, doi:10.1016/j.bbamem.2007.07.008
Álvarez-Viñas, Souto, Flórez-Fernández, Torres, Bandín et al., Antiviral activity of carrageenans and processing implications, Mar Drugs, doi:10.3390/md19080437
DOI record: { "DOI": "10.2147/ijn.s448005", "ISSN": [ "1178-2013" ], "URL": "http://dx.doi.org/10.2147/IJN.S448005", "author": [ { "ORCID": "http://orcid.org/0000-0002-5053-9704", "affiliation": [], "authenticated-orcid": true, "family": "Yathindranath", "given": "Vinith", "sequence": "first" }, { "affiliation": [], "family": "Safa", "given": "Nura", "sequence": "additional" }, { "affiliation": [], "family": "Tomczyk", "given": "Mateusz", "sequence": "additional" }, { "affiliation": [], "family": "Dolinsky", "given": "Vernon", "sequence": "additional" }, { "affiliation": [], "family": "Miller", "given": "Donald", "sequence": "additional" } ], "container-title": "International Journal of Nanomedicine", "container-title-short": "IJN", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2024, 3, 28 ] ], "date-time": "2024-03-28T06:50:15Z", "timestamp": 1711608615000 }, "deposited": { "date-parts": [ [ 2024, 3, 28 ] ], "date-time": "2024-03-28T06:50:22Z", "timestamp": 1711608622000 }, "indexed": { "date-parts": [ [ 2024, 3, 29 ] ], "date-time": "2024-03-29T01:40:31Z", "timestamp": 1711676431908 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2024, 3 ] ] }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by-nc/3.0/", "content-version": "unspecified", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 3, 1 ] ], "date-time": "2024-03-01T00:00:00Z", "timestamp": 1709251200000 } } ], "link": [ { "URL": "https://www.dovepress.com/getfile.php?fileID=97961", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.dovepress.com/getfile.php?fileID=97961", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "301", "original-title": [], "page": "3087-3108", "prefix": "10.2147", "published": { "date-parts": [ [ 2024, 3 ] ] }, "published-online": { "date-parts": [ [ 2024, 3 ] ] }, "publisher": "Informa UK Limited", "reference": [ { "key": "ref1", "unstructured": "Available from: https://covid19.who.int/. Accessed March 7, 2023. WHO COVID-19 dashboard" }, { "DOI": "10.4103/jfmpc.jfmpc_839_21", "author": "Pustake", "doi-asserted-by": "publisher", "first-page": "10", "journal-title": "J Family Med Prim Care", "key": "ref2", "volume": "11", "year": "2022" }, { "DOI": "10.12998/wjcc.v10.i1.1", "author": "Ren", "doi-asserted-by": "publisher", "first-page": "1", "journal-title": "World J Clin Cases", "key": "ref3", "volume": "10", "year": "2022" }, { "DOI": "10.1002/rmv.2136", "author": "Giovane", "doi-asserted-by": "publisher", "first-page": "e2136", "journal-title": "Rev Med Virol", "key": "ref4", "volume": "30", "year": "2020" }, { "DOI": "10.1016/j.cell.2020.02.052", "author": "Hoffmann", "doi-asserted-by": "publisher", "first-page": "271", "journal-title": "Cell", "key": "ref5", "volume": "181", "year": "2020" }, { "DOI": "10.3390/ph15070783", "author": "Arias", "doi-asserted-by": "publisher", "first-page": "783", "journal-title": "Pharmaceuticals", "key": "ref6", "volume": "15", "year": "2022" }, { "DOI": "10.1186/s40001-021-00626-3", "author": "Niknam", "doi-asserted-by": "publisher", "first-page": "6", "journal-title": "Eur J Med Res", "key": "ref7", "volume": "27", "year": "2022" }, { "DOI": "10.1186/s12985-023-01973-9", "author": "Panahi", "doi-asserted-by": "publisher", "first-page": "23", "journal-title": "Virol J", "key": "ref8", "volume": "20", "year": "2023" }, { "DOI": "10.1056/NEJMoa2119657", "author": "Sullivan", "doi-asserted-by": "publisher", "first-page": "1700", "journal-title": "N Engl J Med", "key": "ref9", "volume": "386", "year": "2022" }, { "DOI": "10.1001/jama.2021.0202", "author": "Gottlieb", "doi-asserted-by": "publisher", "first-page": "632", "journal-title": "JAMA", "key": "ref10", "volume": "325", "year": "2021" }, { "DOI": "10.1038/s41579-021-00630-8", "author": "Yang", "doi-asserted-by": "publisher", "first-page": "685", "journal-title": "Nat Rev Microbiol", "key": "ref11", "volume": "19", "year": "2021" }, { "DOI": "10.1038/s41579-020-00468-6", "author": "V’kovski", "doi-asserted-by": "publisher", "first-page": "155", "journal-title": "Nat Rev Microbiol", "key": "ref12", "volume": "19", "year": "2021" }, { "DOI": "10.1056/NEJMoa2034577", "author": "Polack", "doi-asserted-by": "publisher", "first-page": "2603", "journal-title": "N Engl J Med", "key": "ref13", "volume": "383", "year": "2020" }, { "DOI": "10.3389/fimmu.2021.712122", "author": "Walsh", "doi-asserted-by": "publisher", "first-page": "712122", "journal-title": "Front Immunol", "key": "ref14", "volume": "12", "year": "2021" }, { "DOI": "10.1371/journal.pmed.1003495", "author": "Politch", "doi-asserted-by": "publisher", "first-page": "e1003495", "journal-title": "PLoS Med", "key": "ref15", "volume": "18", "year": "2021" }, { "DOI": "10.1038/s41586-022-04797-9", "author": "Sneller", "doi-asserted-by": "publisher", "first-page": "375", "journal-title": "Nature", "key": "ref16", "volume": "606", "year": "2022" }, { "DOI": "10.1002/14651858.CD013825.pub2", "author": "Kreuzberger", "doi-asserted-by": "publisher", "first-page": "Cd013825", "journal-title": "Cochrane Database Syst Rev", "key": "ref17", "volume": "9", "year": "2021" }, { "DOI": "10.1007/s40121-021-00515-6", "author": "Nathan", "doi-asserted-by": "publisher", "first-page": "1933", "journal-title": "Infect Dis Ther", "key": "ref18", "volume": "10", "year": "2021" }, { "DOI": "10.1038/s41586-021-03777-9", "author": "Planas", "doi-asserted-by": "publisher", "first-page": "276", "journal-title": "Nature", "key": "ref19", "volume": "596", "year": "2021" }, { "DOI": "10.1126/sciadv.abf1738", "author": "Chan", "doi-asserted-by": "publisher", "first-page": "eabf1738", "journal-title": "Sci Adv", "key": "ref20", "volume": "7", "year": "2021" }, { "DOI": "10.3389/fimmu.2021.732690", "author": "Kuba", "doi-asserted-by": "publisher", "first-page": "732690", "journal-title": "Front Immunol", "key": "ref21", "volume": "12", "year": "2021" }, { "DOI": "10.1016/j.virol.2006.01.029", "author": "Han", "doi-asserted-by": "publisher", "first-page": "15", "journal-title": "Virology", "key": "ref22", "volume": "350", "year": "2006" }, { "DOI": "10.1016/j.addr.2020.11.007", "author": "Schütz", "doi-asserted-by": "publisher", "first-page": "47", "journal-title": "Adv Drug Deliv Rev", "key": "ref23", "volume": "167", "year": "2020" }, { "DOI": "10.1007/s40262-013-0072-7", "author": "Haschke", "doi-asserted-by": "publisher", "first-page": "783", "journal-title": "Clin Pharmacokinet", "key": "ref24", "volume": "52", "year": "2013" }, { "DOI": "10.1038/s41467-021-24013-y", "author": "Higuchi", "doi-asserted-by": "publisher", "first-page": "3802", "journal-title": "Nat Commun", "key": "ref25", "volume": "12", "year": "2021" }, { "DOI": "10.1002/adma.201802233", "author": "Wei", "doi-asserted-by": "publisher", "first-page": "e1802233", "journal-title": "Adv Mater", "key": "ref26", "volume": "30", "year": "2018" }, { "DOI": "10.1073/pnas.2014352117", "author": "Rao", "doi-asserted-by": "publisher", "first-page": "27141", "journal-title": "Proc Natl Acad Sci", "key": "ref27", "volume": "117", "year": "2020" }, { "DOI": "10.1038/s41467-020-18880-0", "author": "Jia", "doi-asserted-by": "publisher", "first-page": "5165", "journal-title": "Nat Commun", "key": "ref28", "volume": "11", "year": "2020" }, { "DOI": "10.1172/JCI148517", "author": "Ahn", "doi-asserted-by": "publisher", "first-page": "148517", "journal-title": "J Clin Investig", "key": "ref29", "volume": "131", "year": "2021" }, { "DOI": "10.1016/0003-2697(74)90034-7", "author": "Scopes", "doi-asserted-by": "publisher", "first-page": "277", "journal-title": "Analy Biochem", "key": "ref30", "volume": "59", "year": "1974" }, { "DOI": "10.1016/j.ejphar.2010.12.004", "author": "J-l", "doi-asserted-by": "publisher", "first-page": "17", "journal-title": "Eur J Pharmacol", "key": "ref31", "volume": "654", "year": "2011" }, { "DOI": "10.3390/cancers14215179", "author": "Yathindranath", "doi-asserted-by": "publisher", "first-page": "5179", "journal-title": "Cancers", "key": "ref32", "volume": "14", "year": "2022" }, { "DOI": "10.1021/acsnano.1c05922", "author": "Chen", "doi-asserted-by": "publisher", "first-page": "14022", "journal-title": "ACS Nano", "key": "ref33", "volume": "15", "year": "2021" }, { "DOI": "10.1007/s00018-005-5372-0", "author": "Valenti", "doi-asserted-by": "publisher", "first-page": "2576", "journal-title": "Cell Mol Life Sci", "key": "ref34", "volume": "62", "year": "2005" }, { "DOI": "10.3168/jds.2021-21247", "author": "Wotring", "doi-asserted-by": "publisher", "first-page": "2791", "journal-title": "J Dairy Sci", "key": "ref35", "volume": "105", "year": "2022" }, { "DOI": "10.3390/md19080437", "author": "Álvarez-viñas", "doi-asserted-by": "publisher", "first-page": "437", "journal-title": "Mar Drugs", "key": "ref36", "volume": "19", "year": "2021" }, { "DOI": "10.1016/j.ebiom.2021.103255", "author": "Hoffmann", "doi-asserted-by": "publisher", "first-page": "103255", "journal-title": "EBioMedicine", "key": "ref37", "volume": "65", "year": "2021" }, { "DOI": "10.1038/mtna.2012.28", "author": "Belliveau", "doi-asserted-by": "publisher", "first-page": "e37", "journal-title": "Mol Ther Nucleic Acids", "key": "ref38", "volume": "1", "year": "2012" }, { "DOI": "10.1038/s41578-021-00358-0", "author": "Hou", "doi-asserted-by": "publisher", "first-page": "1078", "journal-title": "Nat Rev Mater", "key": "ref39", "volume": "6", "year": "2021" }, { "DOI": "10.3390/pharmaceutics5030498", "author": "Tam", "doi-asserted-by": "publisher", "first-page": "498", "journal-title": "Pharmaceutics", "key": "ref40", "volume": "5", "year": "2013" }, { "DOI": "10.3390/nano9030474", "author": "Bayón-Cordero", "doi-asserted-by": "publisher", "first-page": "474", "journal-title": "Nanomaterials", "key": "ref41", "volume": "9", "year": "2019" }, { "DOI": "10.1016/j.bbamem.2007.07.008", "author": "Zhao", "doi-asserted-by": "publisher", "first-page": "2764", "journal-title": "Biochim Biophys Acta", "key": "ref42", "volume": "1768", "year": "2007" }, { "DOI": "10.1016/S0005-2736(00)00343-6", "author": "Semple", "doi-asserted-by": "publisher", "first-page": "152", "journal-title": "Biochim Biophys Acta", "key": "ref43", "volume": "1510", "year": "2001" }, { "DOI": "10.1002/smll.202103025", "author": "van der Meel", "doi-asserted-by": "publisher", "first-page": "2103025", "journal-title": "Small", "key": "ref44", "volume": "17", "year": "2021" }, { "DOI": "10.1016/j.ejps.2022.106234", "author": "Tam", "doi-asserted-by": "publisher", "first-page": "106234", "journal-title": "Eur J Pharm Sci", "key": "ref45", "volume": "176", "year": "2022" }, { "DOI": "10.1021/nn301630n", "author": "Hak", "doi-asserted-by": "publisher", "first-page": "5648", "journal-title": "ACS Nano", "key": "ref46", "volume": "6", "year": "2012" }, { "DOI": "10.1002/smll.201001349", "author": "Papp", "doi-asserted-by": "publisher", "first-page": "2900", "journal-title": "Small", "key": "ref47", "volume": "6", "year": "2010" }, { "DOI": "10.1002/chem.200900923", "author": "Martinez-Avila", "doi-asserted-by": "publisher", "first-page": "9874", "journal-title": "Chem Eur J", "key": "ref48", "volume": "15", "year": "2009" }, { "DOI": "10.1002/smll.200902384", "author": "Baram-Pinto", "doi-asserted-by": "publisher", "first-page": "1044", "journal-title": "Small", "key": "ref49", "volume": "6", "year": "2010" }, { "DOI": "10.1021/ja710321g", "author": "Bowman", "doi-asserted-by": "publisher", "first-page": "6896", "journal-title": "J Am Chem Soc", "key": "ref50", "volume": "130", "year": "2008" }, { "DOI": "10.1038/s41467-021-27893-2", "author": "El-Shennawy", "doi-asserted-by": "publisher", "first-page": "405", "journal-title": "Nat Commun", "key": "ref51", "volume": "13", "year": "2022" }, { "DOI": "10.1021/acsami.7b09931", "author": "Chen", "doi-asserted-by": "publisher", "first-page": "39953", "journal-title": "ACS Appl Mater Interfaces", "key": "ref52", "volume": "9", "year": "2017" }, { "DOI": "10.1039/D1CC02267A", "author": "Mesias", "doi-asserted-by": "publisher", "first-page": "6979", "journal-title": "Chem Comm", "key": "ref53", "volume": "57", "year": "2021" }, { "DOI": "10.1038/s41591-020-0868-6", "author": "Sungnak", "doi-asserted-by": "publisher", "first-page": "681", "journal-title": "Nat Med", "key": "ref54", "volume": "26", "year": "2020" }, { "DOI": "10.1016/j.ebiom.2021.103316", "author": "Nikiforuk", "doi-asserted-by": "publisher", "first-page": "103316", "journal-title": "eBioMedicine", "key": "ref55", "volume": "66", "year": "2021" }, { "DOI": "10.1016/0169-409X(93)90015-V", "author": "Gizurarson", "doi-asserted-by": "publisher", "first-page": "329", "journal-title": "Adv Drug Deliv Rev", "key": "ref56", "volume": "11", "year": "1993" }, { "DOI": "10.1038/s44222-022-00012-6", "author": "Cahn", "doi-asserted-by": "publisher", "first-page": "83", "journal-title": "Nat Rev Bioeng", "key": "ref57", "volume": "1", "year": "2023" }, { "DOI": "10.1016/S0168-3659(99)00233-3", "author": "Huang", "doi-asserted-by": "publisher", "first-page": "63", "journal-title": "J Control Release", "key": "ref58", "volume": "65", "year": "2000" }, { "DOI": "10.1021/acsnano.5b03876", "author": "Xu", "doi-asserted-by": "publisher", "first-page": "9217", "journal-title": "ACS Nano", "key": "ref59", "volume": "9", "year": "2015" }, { "DOI": "10.1016/j.ejpb.2005.10.011", "author": "Serra", "doi-asserted-by": "publisher", "first-page": "11", "journal-title": "Eur J Pharm Biopharm", "key": "ref60", "volume": "63", "year": "2006" } ], "reference-count": 60, "references-count": 60, "relation": {}, "resource": { "primary": { "URL": "https://www.dovepress.com/lipid-nanoparticle-based-inhibitors-for-sars-cov-2-host-cell-infection-peer-reviewed-fulltext-article-IJN" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Organic Chemistry", "Drug Discovery", "General Medicine", "Biomaterials", "Bioengineering", "Biophysics", "Pharmaceutical Science" ], "subtitle": [], "title": "Lipid Nanoparticle-Based Inhibitors for SARS-CoV-2 Host Cell Infection", "type": "journal-article", "volume": "Volume 19" }